Fulcrum Therapeutics Inc [NASDAQ: FULC] gained 45.96% on the last trading session, reaching $12.99 price per share at the time.
Fulcrum Therapeutics Inc represents 54.11 million in outstanding shares, while the company has a total market value of $702.99 million with the latest information. FULC stock price has been found in the range of $12.74 to $15.7399.
If compared to the average trading volume of 666.11K shares, FULC reached a trading volume of 24673984 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Fulcrum Therapeutics Inc [FULC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FULC shares is $17.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FULC stock is a recommendation set at 1.56. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Fulcrum Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 24, 2025. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $4 to $12. The new note on the price target was released on July 29, 2025, representing the official price target for Fulcrum Therapeutics Inc stock. Previously, the target price had yet another raise to $12, while Leerink Partners analysts kept a Outperform rating on FULC stock.
The Price to Book ratio for the last quarter was 3.54, with the Price to Cash per share for the same quarter was set at 3.71.
Trading performance analysis for FULC stock
Fulcrum Therapeutics Inc [FULC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.61. With this latest performance, FULC shares gained by 69.80% in over the last four-week period, additionally plugging by 82.44% over the last 6 months – not to mention a rise of 176.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FULC stock in for the last two-week period is set at 67.85, with the RSI for the last a single of trading hit 1.57, and the three-weeks RSI is set at 1.12 for Fulcrum Therapeutics Inc [FULC]. The present Moving Average for the last 50 days of trading for this stock 9.40, while it was recorded at 9.73 for the last single week of trading, and 6.65 for the last 200 days.
Fulcrum Therapeutics Inc (FULC) Capital Structure & Debt Analysis
According to recent financial data for Fulcrum Therapeutics Inc. ( FULC), the Return on Equity (ROE) stands at -31.21%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -28.80%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Fulcrum Therapeutics Inc’s Return on Invested Capital (ROIC) is -35.03%, showcasing its effectiveness in deploying capital for earnings.
Fulcrum Therapeutics Inc (FULC) Efficiency & Liquidity Metrics
Based on Fulcrum Therapeutics Inc’s (FULC) latest financial statements, the Debt-to-Equity Ratio is 0.04%, indicating its reliance on debt financing relative to shareholder equity.
Fulcrum Therapeutics Inc (FULC) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Fulcrum Therapeutics Inc. (FULC) effectively leverages its workforce, generating an average of -$1580222.22 per employee. The company’s liquidity position is robust, with a Current Ratio of 17.70% and a Quick Ratio of 17.70%, indicating strong ability to cover short-term liabilities.
Fulcrum Therapeutics Inc [FULC]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Fulcrum Therapeutics Inc posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.29/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FULC.
An analysis of Institutional ownership at Fulcrum Therapeutics Inc [FULC]
There are presently around $100.18%, or 101.71%% of FULC stock, in the hands of institutional investors. The top three institutional holders of FULC stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 11.61 million shares, which is approximately 18.6636%. RTW INVESTMENTS, LP, holding 5.85 million shares of the stock with an approximate value of $$36.24 million in FULC stocks shares; and RTW INVESTMENTS, LP, currently with $$33.05 million in FULC stock with ownership which is approximately 8.5684%.
